[Stapylococcemia in patients undergoing hemodialysis through arteriovenous fistulas. Incidence of valvular localizations].
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001132:Arm / Q000098:blood supply; D001158:Arteries; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects*; D002512:Cephalothin / Q000627:therapeutic use; D005334:Fever / Q000209:etiology; D005839:Gentamicins / Q000627:therapeutic use; D006349:Heart Valve Diseases / Q000209:etiology*; D006801:Humans; D010689:Phlebitis / Q000209:etiology*; D011379:Prognosis; D006435:Renal Dialysis / Q000009:adverse effects*; D012501:Saphenous Vein; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D014680:Veins
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D002512:Cephalothin
Staphylococcèmies chey les malades hèmodialysès au moyen de fistules artèrioveineuses. Frèquence des localisations valvulaires.